In the last seven years, since the introduction of the targeted therapies, remarkable progress has transpired that has transformed the therapeutic landscape for metastatic renal cell carcinoma.
Toni K. Choueiri, MD2
Advertisement
Articles by Toni K. Choueiri, MD2
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Zipalertinib Plus Chemotherapy Improves PFS in First-Line EGFR Exon 20 Insertion+ NSCLC
3
Dr Van Gorp on PFS Data With TUB-040 in Platinum-Resistant Ovarian Cancer
4
Neoadjuvant Ivonescimab Plus Chemotherapy Yields pCRs in Resectable HNSCC
5